AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

 AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

AstraZeneca Reports Imfinzi (durvalumab) & tremelimumab Results in P-III EAGLE trial for Advanced Head and Neck Cancer

Shots:

  • The P-III EAGLE study involved assessing of Imfinzi as monothx or Imfinzi + tremelimumab vs SoC CT in patients with recurrent or metastatic HNSCC who experienced progression following Pt-based CT, at 169 centers across 24 countries
  • The P-III EAGLE study results demonstrated that it didn’t met 1EPs as OS and has shown safety and well-tolerated signs in patients 
  • Imfinzi (durvalumab) is a mAb, binds with PD-L1 and blocks its interaction with PD-1 and CD80, is approved in 40 countries including the US, EU and Japan for Stage III NSCLC. Tremelimumab is a mAb, used for targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Click here to read full press release/ article | Ref: AstraZeneca | Image Source: DW

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post